Literature DB >> 21952167

Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice.

Jiehua Zhou1, C Preston Neff, Xiaoxuan Liu, Jane Zhang, Haitang Li, David D Smith, Piotr Swiderski, Tawfik Aboellail, Yuanyu Huang, Quan Du, Zicai Liang, Ling Peng, Ramesh Akkina, John J Rossi.   

Abstract

We evaluated the in vivo efficacy of structurally flexible, cationic PAMAM dendrimers as a small interfering RNA (siRNA) delivery system in a Rag2(-)/-γc-/- (RAG-hu) humanized mouse model for HIV-1 infection. HIV-infected humanized Rag2-/-γc-/- mice (RAG-hu) were injected intravenously (i.v.) with dendrimer-siRNA nanoparticles consisting of a cocktail of dicer substrate siRNAs (dsiRNAs) targeting both viral and cellular transcripts. We report in this study that the dendrimer-dsiRNA treatment suppressed HIV-1 infection by several orders of magnitude and protected against viral induced CD4(+) T-cell depletion. We also demonstrated that follow-up injections of the dendrimer-cocktailed dsiRNAs following viral rebound resulted in complete inhibition of HIV-1 titers. Biodistribution studies demonstrate that the dendrimer-dsiRNAs preferentially accumulate in peripheral blood mononuclear cells (PBMCs) and liver and do not exhibit any discernable toxicity. These data demonstrate for the first time efficacious combinatorial delivery of anti-host and -viral siRNAs for HIV-1 treatment in vivo. The dendrimer delivery approach therefore represents a promising method for systemic delivery of combinations of siRNAs for treatment of HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21952167      PMCID: PMC3242666          DOI: 10.1038/mt.2011.207

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  45 in total

Review 1.  RNAi as a treatment for HIV-1 infection.

Authors:  John J Rossi
Journal:  Biotechniques       Date:  2006-04       Impact factor: 1.993

2.  Bispecific short hairpin siRNA constructs targeted to CD4, CXCR4, and CCR5 confer HIV-1 resistance.

Authors:  Joseph Anderson; Akhil Banerjea; Ramesh Akkina
Journal:  Oligonucleotides       Date:  2003

Review 3.  Strategies for silencing human disease using RNA interference.

Authors:  Daniel H Kim; John J Rossi
Journal:  Nat Rev Genet       Date:  2007-03       Impact factor: 53.242

4.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.

Authors:  A Fire; S Xu; M K Montgomery; S A Kostas; S E Driver; C C Mello
Journal:  Nature       Date:  1998-02-19       Impact factor: 49.962

5.  T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice.

Authors:  Priti Kumar; Hong-Seok Ban; Sang-Soo Kim; Haoquan Wu; Todd Pearson; Dale L Greiner; Amale Laouar; Jiahong Yao; Viraga Haridas; Katsuyoshi Habiro; Yong-Guang Yang; Ji-Hoon Jeong; Kuen-Yong Lee; Yong-Hee Kim; Sung Wan Kim; Matthias Peipp; Georg H Fey; N Manjunath; Leonard D Shultz; Sang-Kyung Lee; Premlata Shankar
Journal:  Cell       Date:  2008-08-07       Impact factor: 41.582

6.  Ethylendiamine core PAMAM dendrimers/siRNA complexes as in vitro silencing agents.

Authors:  A P Perez; E L Romero; M J Morilla
Journal:  Int J Pharm       Date:  2009-07-03       Impact factor: 5.875

7.  PAMAM dendrimers mediate siRNA delivery to target Hsp27 and produce potent antiproliferative effects on prostate cancer cells.

Authors:  Xiao-Xuan Liu; Palma Rocchi; Fan-Qi Qu; Shu-Quan Zheng; Zi-Cai Liang; Martin Gleave; Juan Iovanna; Ling Peng
Journal:  ChemMedChem       Date:  2009-08       Impact factor: 3.466

8.  Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs.

Authors:  Gunter Meister; Markus Landthaler; Agnieszka Patkaniowska; Yair Dorsett; Grace Teng; Thomas Tuschl
Journal:  Mol Cell       Date:  2004-07-23       Impact factor: 17.970

9.  Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy.

Authors:  Jiehua Zhou; Haitang Li; Shirley Li; John Zaia; John J Rossi
Journal:  Mol Ther       Date:  2008-05-06       Impact factor: 11.454

Review 10.  Interfering with disease: a progress report on siRNA-based therapeutics.

Authors:  Antonin de Fougerolles; Hans-Peter Vornlocher; John Maraganore; Judy Lieberman
Journal:  Nat Rev Drug Discov       Date:  2007-06       Impact factor: 84.694

View more
  52 in total

Review 1.  HIV-1 immunopathogenesis in humanized mouse models.

Authors:  Liguo Zhang; Lishan Su
Journal:  Cell Mol Immunol       Date:  2012-04-16       Impact factor: 11.530

2.  Efficient inhibition of human immunodeficiency virus replication using novel modified microRNA-30a targeting 3'-untranslated region transcripts.

Authors:  Ahmad Nejati; Shohreh Shahmahmoodi; Ehsan Arefian; Zabihollah Shoja; Sayed-Mahdi Marashi; Hamideh Tabatabaie; Yaghoub Mollaei-Kandelous; Masoud Soleimani; Rakhshandeh Nategh
Journal:  Exp Ther Med       Date:  2016-03-02       Impact factor: 2.447

Review 3.  New generation humanized mice for virus research: comparative aspects and future prospects.

Authors:  Ramesh Akkina
Journal:  Virology       Date:  2013-01-05       Impact factor: 3.616

4.  Mastering Dendrimer Self-Assembly for Efficient siRNA Delivery: From Conceptual Design to In Vivo Efficient Gene Silencing.

Authors:  Chao Chen; Paola Posocco; Xiaoxuan Liu; Qiang Cheng; Erik Laurini; Jiehua Zhou; Cheng Liu; Yang Wang; Jingjie Tang; Valentina Dal Col; Tianzhu Yu; Suzanne Giorgio; Maurizio Fermeglia; Fanqi Qu; Zicai Liang; John J Rossi; Minghua Liu; Palma Rocchi; Sabrina Pricl; Ling Peng
Journal:  Small       Date:  2016-05-31       Impact factor: 13.281

Review 5.  Current humanized mouse models for studying human immunology and HIV-1 immuno-pathogenesis.

Authors:  LiGuo Zhang; Eric Meissner; JianZhu Chen; LiShan Su
Journal:  Sci China Life Sci       Date:  2010-03-07       Impact factor: 6.038

Review 6.  Recent advances in RNAi-based strategies for therapy and prevention of HIV-1/AIDS.

Authors:  Manjunath N Swamy; Haoquan Wu; Premlata Shankar
Journal:  Adv Drug Deliv Rev       Date:  2016-03-21       Impact factor: 15.470

7.  Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity.

Authors:  Jiehua Zhou; Sangeetha Satheesan; Haitang Li; Marc S Weinberg; Kevin V Morris; John C Burnett; John J Rossi
Journal:  Chem Biol       Date:  2015-03-05

Review 8.  Studies of retroviral infection in humanized mice.

Authors:  Matthew D Marsden; Jerome A Zack
Journal:  Virology       Date:  2015-02-11       Impact factor: 3.616

Review 9.  Progress toward in vivo use of siRNAs-II.

Authors:  Garrett R Rettig; Mark A Behlke
Journal:  Mol Ther       Date:  2011-12-20       Impact factor: 11.454

10.  Inhibition of hepatitis C virus replication by intracellular delivery of multiple siRNAs by nanosomes.

Authors:  Partha K Chandra; Anup K Kundu; Sidhartha Hazari; Sruti Chandra; Lili Bao; Tara Ooms; Gilbert F Morris; Tong Wu; Tarun K Mandal; Srikanta Dash
Journal:  Mol Ther       Date:  2012-05-22       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.